Healthcare Headlines: EU Approves GSK's RSV Shot, Eisai and Biogen Face Alzheimer Drug Rejection, WHO Fights Polio in Gaza

This summary covers the latest health news, including the EU's approval of GSK's RSV vaccine for adults aged 50-59, the rejection of Eisai and Biogen's Alzheimer's drug, WHO's shipment of polio vaccines to Gaza, and other significant health developments.

The European Union health regulator has recommended the expanded use of GSK's RSV vaccine for adults aged 50-59. The move, endorsed by the European Medicines Agency's Committee for Medicinal Products for Human Use, awaits formal approval by the European Commission.

In a setback for Eisai and Biogen, the EU’s drugs regulator rejected their Leqembi treatment for early Alzheimer's disease, citing risks of brain swelling that outweigh its mild cognitive benefits.

The World Health Organization is dispatching over one million polio vaccines to Gaza following the detection of the virus in sewage samples. WHO Director-General Tedros Adhanom Ghebreyesus emphasized the need for immediate action to protect children from potential outbreaks.

The Netherlands has gained EU approval for €2 billion in state aid to construct a nuclear reactor producing medical isotopes for cancer treatment.

Indivior has agreed to an $86 million settlement with 16 U.S. states over allegations that its buprenorphine-based products contributed to the opioid crisis.

The U.S. FDA has issued warnings about dosing errors in compounded versions of Novo Nordisk's weight-loss and diabetes drugs, following adverse event reports.

The U.S. has acknowledged spreading propaganda against China's Sinovac vaccine in the Philippines during the COVID-19 pandemic, according to a revealed document.

Steward Health Care will close two Massachusetts hospitals after failing to find buyers, following its bankruptcy filing earlier this year.

Brazil's government has declared an end to the Newcastle disease outbreak in poultry, which had halted exports, and awaits the lifting of international trade embargoes.

Abbott Laboratories has been ordered to pay $495 million after a jury found its infant formula caused severe disease in a premature child, marking the first of many similar claims.